Safety and efficacy of pegylated liposomal doxorubicinbased adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 7319-7326

  Lien, Ming Yu ^a   Liu, Liang Chih ^b   Wang, Hwei Chung ^c   Yeh, Ming Hsin ^d   Chen, Chih Jung ^e   Yeh, Su Peng ^e   Bai, Li Yuan ^a   Liao, Yu Min ^a   Lin, Chen Yuan ^e   Hsieh, Ching Yun ^a   Lin, Ching Chan ^a   Li, Long Yuan ^b   Lin, Po Han ^a   Chiu, Chang Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Surgery ^*  (Taiwan)

^c Pediatric Dentistry   (Taiwan)

^d Graduate Institute of Clinical Medicine   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adjuvant chemotherapy; Anthracycline; Pegylated liposomal doxorubicin; Triplenegative breast cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; HAND FOOT SYNDROME; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; POST MASTECTOMY RADIATION THERAPY; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HAND-FOOT SYNDROME; MIDDLE AGED; MORTALITY; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE;

ANTIBIOTICS, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HAND-FOOT SYNDROME; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; POLYETHYLENE GLYCOLS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84918555748     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007
2. Yamamoto Y and Iwase H: Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 15: 341-351, 2010
3. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P and Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115: 423-428, 2009
4. Joensuu H and Gligorov J: Adjuvant treatments for triplenegative breast cancers. Ann Oncol 23(Suppl 6): vi40-45, 2012
5. Henderson IC: Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park) 25: 115-124, 127, 2011
6. Swain SM, Whaley FS and Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-2879, 2003
7. Selleri S, Seltmann H, Gariboldi S, Shirai YF, Balsari A, Zouboulis CC and Rumio C: Doxorubicin-induced alopecia is associated with sebaceous gland degeneration. J Invest Dermatol 126: 711-720, 2006
8. Duggan ST and Keating GM: Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposis sarcoma. Drugs 71: 2531-2558, 2011
9. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L and Tendler C: Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22: 3893-3901, 2004
10. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E and Gabizon A: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86: 72-78, 1999
11. Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan Z and Rackoff WRL: Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-Adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 27: 4522-4529, 2009
12. Green H, Stal O, Bachmeier K, Backlund LM, Carlsson L, Hansen J, Lagerlund M, Norberg B, Franzen A, Aleskog A and Malmstrom A: Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified. Cancer Lett 313: 145-153, 2011
13. Greene F, Edge S, Byrd D, Compton C, Trotti A (eds.). American Joint Committee on Cancer (AJCC) Staging Manual, 2010
14. Frierson HF Jr., Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC and Wilbur DC: Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103: 195-198, 1995
15. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ and Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011
16. National Cancer Institute: National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 4.0. (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf)
17. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr., Von Hoff AL, Rozencweig M and Muggia FM: Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 91: 710-717, 1979
18. Chatterjee K, Zhang J, Honbo N and Karliner JS: Doxorubicin cardiomyopathy. Cardiology 115: 155-162, 2010
19. Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998
20. OBrien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L and Tendler C: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449, 2004
21. Batist G, Harris L, Azarnia N, Lee LW and Daza-Ramirez P: Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 17: 587-595, 2006
22. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC and Lee LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19: 1444-1454, 2001
23. Crivellari D, Gray KP, Dellapasqua S, Puglisi F, Ribi K, Price KN, Lang I, Gianni L, Spazzapan S, Pinotti G, Luthi JM, Gelber RD, Regan MM, Colleoni M, Castiglione-Gertsch M, Maibach R, Rabaglio M, Coates AS and Goldhirsch A: Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast 22: 130-137, 2013
24. Eitan R, Fishman A, Meirovitz M, Goldenberg H, Amit A, Koren C, Schineider Y, Rosengarten O, Neuman A, Keren-Rosenberg S and Safra T: Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis. Anticancer Drugs 25(1): 101-105, 2014
25. Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G and Liu D: Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-Analysis. Exp Hematol Oncol 1: 10, 2012
26. Early Breast Cancer Trialists Collaborative G, Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI and Wood WC: Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patientlevel meta-Analysis of randomised trials. Lancet 371: 29-40, 2008
27. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A and Vogel C: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302-2313, 2005
28. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M and Vogel C: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27: 1168-1176, 2009
29. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S and Scambia G: Pegylated liposomal doxorubicin-related palmarplantar erythrodysesthesia (hand-foot syndrome). Ann Oncol 18: 1159-1164, 2007
30. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture ME, Lademann J and Hauschild A: Pegylated liposomal doxorubicinassociated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44: 781-790, 2008
31. Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ and Chen G: Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23: 1348-1353, 2012
32. Yokomichi N, Nagasawa T, Coler-Reilly A, Suzuki H, Kubota Y, Yoshioka R, Tozawa A, Suzuki N and Yamaguchi Y: Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal Doxorubicin. Hum Cell 26: 8-18, 2013.